Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve the symptoms of patients with treatment-resistant depression after four weeks, the company announced on Feb. 18.
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve the symptoms of patients with treatment-resistant depression after four weeks, the company announced on Feb. 18.
